GILEAD SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.38 USD | +0.32% |
|
-2.39% | -17.98% |
| 02:56pm | BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89 | MT |
| 02:15pm | Leerink Partners Adjusts Gilead Sciences Price Target to $74 From $79 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
66.16
USD
Average target price
85.58
USD
Spread / Average Target
+29.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.98% | 82.5B | |
| +25.29% | 672B | |
| +24.08% | 550B | |
| -6.52% | 351B | |
| +14.82% | 317B | |
| +6.86% | 292B | |
| +3.25% | 211B | |
| +0.53% | 203B | |
| -10.51% | 144B | |
| -7.74% | 141B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences Unit Receives Positive CHMP Opinion for Lymphoblastic Leukemia Treatment in Adults
